MX392523B - Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar - Google Patents
Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de pparInfo
- Publication number
- MX392523B MX392523B MX2020011100A MX2020011100A MX392523B MX 392523 B MX392523 B MX 392523B MX 2020011100 A MX2020011100 A MX 2020011100A MX 2020011100 A MX2020011100 A MX 2020011100A MX 392523 B MX392523 B MX 392523B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- diseases
- ppar agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020011100A MX2020011100A (es) | 2022-05-23 |
| MX392523B true MX392523B (es) | 2025-03-24 |
Family
ID=57200096
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011100A MX392523B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
| MX2018004295A MX380281B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmacéuticas y métodos de uso de agonistas de ppar. |
| MX2020011099A MX392524B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004295A MX380281B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmacéuticas y métodos de uso de agonistas de ppar. |
| MX2020011099A MX392524B (es) | 2015-10-07 | 2016-10-05 | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (enExample) |
| EP (3) | EP3770146B1 (enExample) |
| JP (2) | JP6657413B2 (enExample) |
| KR (2) | KR102667385B1 (enExample) |
| CN (3) | CN113024467B (enExample) |
| AU (3) | AU2016333963C1 (enExample) |
| BR (1) | BR112018006866B1 (enExample) |
| CA (1) | CA3000431A1 (enExample) |
| CO (1) | CO2018004473A2 (enExample) |
| DK (1) | DK3359528T3 (enExample) |
| EA (1) | EA037371B1 (enExample) |
| ES (3) | ES2906379T3 (enExample) |
| HU (1) | HUE058154T2 (enExample) |
| IL (3) | IL258225B (enExample) |
| JO (3) | JO3738B1 (enExample) |
| MA (2) | MA52098A (enExample) |
| MX (3) | MX392523B (enExample) |
| MY (1) | MY203081A (enExample) |
| PH (1) | PH12018500762A1 (enExample) |
| PL (1) | PL3359528T3 (enExample) |
| PT (1) | PT3359528T (enExample) |
| SG (1) | SG10201906400SA (enExample) |
| TW (3) | TWI730408B (enExample) |
| UA (1) | UA122237C2 (enExample) |
| WO (1) | WO2017062468A1 (enExample) |
| ZA (4) | ZA201802029B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3770146B1 (en) * | 2015-10-07 | 2024-07-24 | Astellas Engineered Small Molecules US, Incorporated | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109071459B (zh) | 2016-04-13 | 2022-08-16 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物以及它们的使用方法 |
| MA46459B1 (fr) * | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
| KR20190057129A (ko) * | 2016-10-05 | 2019-05-27 | 미토브리지, 인크. | Ppar 작용제 화합물의 결정형 및 염 형태 |
| WO2021046081A1 (en) * | 2019-09-05 | 2021-03-11 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CA3221429A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) * | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| WO2000050391A1 (en) | 1999-02-26 | 2000-08-31 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| PL361054A1 (en) | 2000-08-17 | 2004-09-20 | Pfizer Inc. | Substituted imidazoles as tafia inhibitors |
| DK1537078T3 (da) * | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| US7820682B2 (en) | 2002-10-03 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | LPA receptor antagonist |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| KR20060080214A (ko) | 2003-09-26 | 2006-07-07 | 니뽄 다바코 산교 가부시키가이샤 | 잔여 리포프로테인 생산 저해 방법 |
| KR20070047338A (ko) | 2004-09-06 | 2007-05-04 | 에프. 호프만-라 로슈 아게 | 4-아미노메틸 벤즈아미딘 유도체 및 그의 ⅶａ 인자억제제로서의 용도 |
| MX2007009343A (es) | 2005-02-15 | 2007-09-21 | Hoffmann La Roche | Derivados de amida como activadores de receptor activado por proliferador de peroxisomas. |
| JP2009507846A (ja) * | 2005-09-07 | 2009-02-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| US7723369B2 (en) | 2006-01-30 | 2010-05-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors |
| US20100261758A1 (en) | 2006-03-28 | 2010-10-14 | Novartis Ag | Heterocyclic amides for use as pharmaceuticals |
| AU2007239283B2 (en) | 2006-04-18 | 2013-02-07 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor delta |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) * | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| US20100063041A1 (en) | 2007-03-07 | 2010-03-11 | Ho-Sang Moon | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| JP2011507970A (ja) | 2007-12-28 | 2011-03-10 | ザ ソーク インスティテュート フォー バイオロジカル スタディーズ | 筋肉の能力および緊張を向上させるための方法 |
| WO2014033088A1 (en) | 2012-08-28 | 2014-03-06 | Koc Universitesi | Bone plate |
| EP2981522A4 (en) | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| WO2016057658A1 (en) | 2014-10-08 | 2016-04-14 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EP3770146B1 (en) | 2015-10-07 | 2024-07-24 | Astellas Engineered Small Molecules US, Incorporated | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN109071459B (zh) | 2016-04-13 | 2022-08-16 | 米托布里奇公司 | Ppar激动剂、化合物、药物组合物以及它们的使用方法 |
| KR20190057129A (ko) * | 2016-10-05 | 2019-05-27 | 미토브리지, 인크. | Ppar 작용제 화합물의 결정형 및 염 형태 |
| MA46459B1 (fr) | 2016-10-05 | 2021-03-31 | Mitobridge Inc | Méthode de traitement de lésions rénales aiguës |
| AU2017388376B2 (en) * | 2016-12-30 | 2022-01-06 | Mitobridge, Inc. | Poly-ADP ribose polymerase (PARP) inhibitors |
-
2016
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392523B (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2018002814A1 (es) | Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel. | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| MX2018012538A (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| CO2017002312A2 (es) | Compuestos bicíclicos sustituidos | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| WO2016057658A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| CL2017003025A1 (es) | Derivados(1,2-b)(1,2,4)de imidazotriazina como agentes antiparasitarios. | |
| WO2016057660A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
| ITUB20169928A1 (it) | Formulazioni farmaceutiche per il trattamento del diabete | |
| EA201992619A3 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| CL2018000336A1 (es) | Composición para el tratamiento de la mucosidad en las branquias de los peces | |
| EA201692164A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |